DUG Foodtech announces the outcome of the rights issue
Reading Time: 7 minutes NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR
Diageo India Releases 2024 ESG Reporting Index Highlights Achievements Across Its ‘Spirit of Progress’ Goals
Reading Time: 6 minutes Diageo India (United Spirits Ltd.), among the country’s leading alco-bev companies, launched its third annual ESG Reporting Index 2024 today, highlighting continued progress in the company’s ‘Spirit of Progress’ ESG action plan. The Reporting Index shares impacts across three key objectives outlined in Diageo’s Spirit
Burjeel Holdings and Response Plus Medical launch $1mn Human Energy Health and Wellbeing Award
Reading Time: 3 minutes Abu Dhabi, United Arab Emirates: Burjeel Holdings, a leading super-specialty healthcare provider in the MENA region, and Response Plus Medical Services (RPM), the largest pre-hospital care and emergency medical services provider in the region, have jointly launched the $1 million Human
#24-379 Listing of Derivatives at NGM
Reading Time: < 1 minute Information about various derivatives that will be listed at NGM. For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market
#24-380 Delisting of Derivatives from NGM
Reading Time: < 1 minute Information about certain derivatives that will be delisted from NGM. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market NGM AB (NGM) is an authorized
BLA for pegzilarginase in the treatment of arginase 1 deficiency (ARG1-D) accepted for priority review by the U.S. FDA
Reading Time: 2 minutes Stockholm, November 5, 2024: Immedica announces today that the Biologics License Application (BLA) for pegzilarginase in the treatment of arginase 1 deficiency (ARG1-D) has been successfully validated and accepted for priority review by the U.S. Food and Drug Administration (FDA). Anders
SOFTSWISS Wins SBC Latinoamérica Award for Help Brazil Initiative
Reading Time: 2 minutes SOFTSWISS has won the Socially Responsible Initiative of the Year nomination at the SBC Awards Latinoamérica 2024 for its impactful ‘Help Brazil’ initiative. This recognition underscores the company’s support for Brazilian communities affected by severe flooding earlier this year and its dedication to
DanCann Pharma A/S: Capital reduction in DanCann Pharma A/S is completed
Reading Time: 3 minutes The capital reduction in DanCann Pharma A/S as resolved on an extraordinary general meeting held on 7 October 2024 has been completed today, 5 November 2024, following expiry of a 4-week notice period (“proklama”). As set out in press release published
Noble Corporation plc Announces Third Quarter 2024 Results and Additional Share Repurchase Authorization
Reading Time: 16 minutes • Closed Diamond acquisition on September 4th • Increased capital return program with additional share repurchase authorization of $400 million • Repurchased 6.9 million of shares in Q3 2024, $0.50 per share dividend declared for Q4 2024, bringing total FY 2024 cash
Synsam invites you to a video presentation of the Q3 report 2024 and a live Q&A session
Reading Time: 2 minutes Synsam AB (publ) will release its interim report for the third quarter 2024 on Tuesday, November 19th at 07:30. At the same time, the company will publish an interview with President and CEO Håkan Lundstedt, together with a presentation of the